Sp192
PANEL DISCUSSION
Date
May 18, 2024
Presenters
Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven
Northwestern University Feinberg School of Medicine
University of California San Diego
University Hospitals Leuven
Tracks
Related Products
Kiron and Kamala Das Symposium — Precision Medicine in IBD: The Road Ahead
SOCIETY: AGA With the expansion of IBD treatment options, there is increasingly the need for predictive models to determine which treatments work best for which patients with IBD…
AN IMBALANCE IN ACTIVE EOSINOPHILS, T HELPER 1, T HELPER 2 AND REGULATORY T CELLS CHARACTERISES FIBROSTRICTURING CROHN'S DISEASE
BACKGROUND: Mesenteric fat is increasingly believed to exert an important influence on intestinal inflammation. A hallmark of severe Crohn's disease (CD) is the accumulation of mesenteric fat around the inflamed intestine, typically in the terminal ileum…
NEUTROPHIL EXTRACELLULAR TRAPS ENHANCE PROFIBROTIC ACTIVITY OF INTESTINAL FIBROBLASTS IN CROHN’S DISEASE THROUGH TLR2/NF-KB PATHWAY
BACKGROUND: Neutrophil extracellular traps (NETs) consist of DNA filaments and cytoplasmic protein granules, extruded by neutrophils after PAD4-dependent activation…
EFFICACY AND SAFETY OF OBEFAZIMOD IN UC PATIENTS AT WEEKS 48 AND 96 OF AN OPEN-LABEL MAINTENANCE STUDY AMONG CLINICAL RESPONDERS AT WEEK 8 OF THE PHASE 2B INDUCTION TRIAL
Obefazimod is an investigational, oral, once-daily, small molecule which enhances expression of microRNA-124 and is currently in phase 3 clinical trials for the treatment of patients with moderately to severely active ulcerative colitis (UC) [1]…
